FIELD: medicine.
SUBSTANCE: invention refers to medicine, cardiology and gene therapy. Disclosed is an agent for treating atherosclerosis, which is a composition for inhibiting gene expression IL7R, IL7, TIGIT, CXCL8, F2RL1, EIF2AK3, TSPYL2, ANXA1, DUSP1 and IL15, closely related to accumulation of cholesterol by human macrophages. Composition consists of Curdlan nanoparticles acting as a carrier and siRNA specific to the above genes.
EFFECT: invention provides creating a low-toxicity composition which suppresses gene expression IL7R, IL7, TIGIT, CXCL8, F2RL1, EIF2AK3, TSPYL2, ANXA1, DUSP1 and IL15.
1 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING PREDISPOSITION TO ATHEROSCLEROSIS DISEASE BASED ON DETERMINING EXPRESSION OF GENES INVOLVED IN ACCUMULATION OF CHOLESTEROL | 2018 |
|
RU2698092C1 |
| METHOD FOR PREDICTING HIGH RISK OF EARLY ATHEROSCLEROSIS | 2019 |
|
RU2752363C2 |
| METHOD FOR LIABILITY TO DEVELOPMENT OF ATHEROSCLEROSIS IN MIDDLE-AGED MEN | 2020 |
|
RU2738975C1 |
| COMPOSITION FOR INTERLEUKINE-4 CYTOKINE GENE SILENCING | 2014 |
|
RU2563989C1 |
| COMPOSITION INHIBITING EXPRESSION OF INTERLEUKIN-4 AND INTERLEUKIN-13 GENES FOR THERAPY OF ALLERGIC RHINITIS | 2018 |
|
RU2710895C1 |
| NUCLEIC ACID HAVING ACTIVITY OF SHORT INTERFERING RNA, VECTOR CONTAINING THIS NUCLEIC ACID COUPLED OPERABLY WITH SEQUENCES OF TRANSCRIPTION REGULATION, AND METHOD OF THEIR APPLICATION FOR INHIBITION OF CELL PROLIFERATION OF HUMAN PANCREATIC ADENOCARCINOMA | 2013 |
|
RU2532842C1 |
| METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF P2X7 RECEPTOR | 2005 |
|
RU2410430C2 |
| SORAFENIB-BASED COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA | 2022 |
|
RU2800071C1 |
| DOUBLE-CHAINED OLIGONUCLEOTIDE SPECIFIC TO CTGF GENE AND COMPOSITION CONTAINING IT FOR PREVENTION AND TREATMENT OF FIBROUS DISEASES AND DISEASES ASSOCIATED WITH RESPIRATORY SYSTEM | 2020 |
|
RU2807108C1 |
| SIRNA CONJUGATE AND PREPARATION METHOD THEREOF | 2013 |
|
RU2571218C2 |
